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Background: While the effects of respiratory motion on measuring metabolic signal in PET/CT scanning are well
known, it is still standard practice in most centres to scan patients while breathing freely with no correction for the
effects of respiratory motion. The aim of this study was to investigate the impact of 4D-PET/CT in classifying lesions
in patients with a radiologically-indeterminate solitary pulmonary nodule.
Methods: Twenty consecutive patients with a solitary pulmonary nodule for investigation were prospectively
recruited and completed a whole-body (WB)-PET/CT and 4D-PET/CT in the same session. The reporting physician
initially classified the nodule using a 5-point scale (Definitely Malignant, Probably Malignant, Indeterminate, Probably
benign, Definitely Benign) on the WB-PET/CT. The physician was then shown the 4D-PET/CT and asked if they
would re-classify the lesion. Frequency, sensitivity, specificity and accuracy values were calculated for WB-PET/CT
alone and then with the addition of the 4D-PET/CT.
Results: There were no changes in the classification for nodules initially classed as either benign or malignant with
the addition of a 4D-PET/CT. However changes were observed between WB and 4D-PET/CT scans in lesions initially
classified as indeterminate. When indeterminate lesions were defined as malignant there was a minor increase in
sensitivity (from 73% to 75%), in specificity (56%-63%) and in accuracy (65%-70%) but these results do not reach
statistical significance. When the Indeterminate lesions were defined as benign there was an increase in sensitivity
(from 55% to 67%) but there was a reduction in the specificity (100%-75%) and accuracy (75%-70%) with the
addition of the 4D-PET/CT but again the results did not reach statistical significance.
Conclusion: The addition of 4D-PET/CT is most likely to have an impact on those nodules initially classified as
indeterminate on standard WB-PET/CT. In lesions classified as benign or malignant on standard WB-PET/CT
the addition of a 4D-PET/CT is less likely to impact lesion classification. While 4D-PET/CT does improve the
measurement of the metabolic signal, it does not overcome inherent limitations of FDG in differentiating a
malignant lesion from inflammatory processes, correct for partial volume effects or compensate for the low
intrinsic FDG-avidity of some malignancies.Background
Solitary pulmonary nodules found incidentally by ana-
tomical imaging modalities such as computerised tomog-
raphy (CT) can present a challenging diagnostic problem.
The use of fluorodeoxyglucose (FDG) positron emis-
sion tomography/computerised tomography (PET/CT)
to characterise a pulmonary nodule with a low to moderate* Correspondence: Jason.Callahan@petermac.org
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unless otherwise stated.pre-test probability of malignancy is now a well-established
diagnostic paradigm [1]. A meta-analysis of the use of
PET/CT to correctly classifying solitary pulmonary nod-
ules found that PET had a sensitivity of 88-96% and speci-
ficity of 70-90% for malignant nodules [2]. However,
despite its high reported sensitivity and specificity one fac-
tor that can confound the interpretation of a PET/CT scan
is the effects of respiratory motion, particularly when the
lesion is small or close to the diaphragm [3].
The aim of using FDG-PET/CT is to measure the
metabolic signal in a lung nodule to differentiate benignl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical use for over two decades [4]. However, a lesion
that is moving due to respiration can have significant
mis-registration between PET and CT scan and an under-
estimation of the true lesion metabolic signal because of
blurring and inappropriate correction for the effects of
soft tissue attenuation [5-7]. If a malignant lesion in not
correctly classified it may lead to a delay in the appropri-
ate management of this lesion. A method to correct the ef-
fects of respiratory motion in PET/CT is respiratory gated
or 4D-PET/CT [8]. This technique entails the recording
of the patients breathing pattern during the acquisition of
the scan, followed by retrospectively creating a cine image
of the patient breathing which removes the blurring ef-
fects of respiration.
While the effects of respiratory motion on measuring
metabolic signal in PET/CT scanning are well known, it
is still standard practice in most centres to scan patients
while breathing freely with no correction for the effects of
respiratory motion. This is mostly due to the increased
complexity of acquiring a 4D PET/CT scan as well as add-
itional equipment cost and scan time. There have been a
number of studies describing improved co-registration
and quantitation in lung lesions with 4D-PET/CT [7,9,10].
However, there has been much less information about
the impact of 4D-PET/CT in the characterisation of
pulmonary nodules as either benign or malignant. The
most comprehensive paper looking at this question was a
retrospective multi- centre study of 155 patients demon-
strating that 4D-PET improved the overall accuracy in
correctly classifying lesions from 85.7% to 92.8% [11]. One
weakness of this study was the relative heterogeneity of
the data in terms of technical specification of the various
cameras, uptake times and acquisition parameters at the
six centres involved in the study. Another study pub-
lished in 2010 by Vicente et al. investigated the impact
of 4D-PET/CT in 42 lung lesions with a very low FDG
signal initially thought to be benign. They found a
change in classification from benign to malignant in
17/42 (40%) cases [12]. To date there is a lack of pro-
spective data in the literature investigating the impact of
using 4D-PET/CT in all patients with a radiologically-
indeterminate SPN.
Hence, the aim of this study was to investigate the im-
pact of 4D-PET/CT in the characterisation of solitary
pulmonary nodules in a routine clinical environment,
using a homogenous acquisition and automated process-




Twenty consecutive patients were prospectively recruited
between November 2011 and July 2012. The study wasapproved by the Peter MacCallum Clinical Governance
and Ethics Committee, and all patients provided written
informed consent. All patients recruited had been referred
to the Peter MacCallum Centre for molecular imaging to
have a FDG-PET/CT to investigate a newly detected soli-
tary pulmonary nodule on CT. Patients were included if
they had a lesion of at least 10 mm in size that was either
deemed of indeterminate nature based on CT appearances
or deemed not to be amenable to biopsy despite being
considered suspicious of malignancy. A patient’s pre-test
risk of malignancy was not an inclusion criterion. Patients
were included regardless of their smoking status or any
prior malignancy.
Patient preparation
After a fasting time of at least six hours, patients were
administered with an FDG dose of 3.2 MBq/kg. Pa-
tients were instructed to lie quietly in an uptake room for
at least 60 minutes. All patients were scanned on a GE-
Discovery690 (GE Medical Systems Milwaukee, WI) with
a mean uptake time of 66 min (range 60-75 mins). Pa-
tients were positioned supine with their arms up and the
infrared reflective marker block for the Varian RPM re-
spiratory tracking system (Varian Medical Systems, Palo
Alto, CA) placed on their abdomen. A standard whole
body PET/CT (WB-PET) scan was completed and then
immediately followed by a 4D-PET/CT centred over the
pulmonary nodule of interest.
Whole Body PET/CT acquisition and processing
Patients were instructed to breathe freely throughout the
whole body PET/CT scan. A CT scan extending from
the base of brain to the proximal thighs was acquired with
the following exposure parameters; 140kv, Smart mA range
40–150, rotation time 0.5 sec, pitch 0.984. This was
immediately followed by a whole body-PET scan with
the following acquisition parameters; 3D frame mode,
192 matrix, 2.5 mins/step, 11slice overlap. The WB-PET
was then reconstructed using OSEM iterative reconstruc-
tion with 2 iteration, 18 subsets, 5 mm Gaussian filter,
time of flight and SharpIR.
4D-PET/CT acquisition and processing
Immediately following the completion of the WB-PET
the patient moved into position to begin the 4D-CT
scan. After moving the patient into position the breath-
ing was allowed to stabilise and recorded using the
Varian Real-Time Patient Monitoring (RPM) system.
The Varian RPM system uses an infrared camera to track
the motion of a box placed on the patient’s abdomen.
Once the breathing had stabilised, a step and shoot 4D-CT
scan was performed using the following parameters: Cine
CT, 10 mA, 140 kV, Cine duration = breathing period +
1.5secs, and the cine time between images = breathing
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spiratory trace was saved and a new trace was established
to use for the 4D-PET.
Immediately after the 4D-CT was completed the pa-
tient was moved into the PET position and the breathing
was allowed to stabilise again before beginning the PET
acquisition. This was acquired as a 3D list mode acquisi-
tion while recoding the patient’s breathing trace. The
4D-PET was acquired for 10 minutes.
The GE automatic phase matching software was used
to process the 4D-PET/CT scan. The 4D-CT was retro-
spectively binned into five frames using the saved re-
spiratory trace. The acquired 3D-List mode PET scan
was retrospectively binned into five frames and each
phase of the 4D-PET was automatically corrected for at-
tenuation with the respective phase of the 4D-CT. The
4D-PET was reconstructed using the same reconstruc-
tion parameters as the WB-PET.
Characterisation of lesions
A five point scale as outlined by Fletcher et. al. [13] was
used to classify the nodules. Fletcher’s five point criteria
are outlined in Table 1.
The scans were reported as a single read where the
physician was first shown the WB-PET/CT scan and
asked to characterize the pulmonary nodule using the
five catagories. The same reporting physician was then
shown the 4D-PET/CT scan and asked if the additional
information changed the classification of the pulmonary
nodule. In order to replicate our usual reporting process,
the reporting clinician was able to review all relevant
clinical information and any prior imaging results. The
reporting physician also incorporated the morphologicTable 1 Fletcher’s PET and CT criteria for rating SPN
Category Relationship between SPN18F-FDG uptake and
malignancy
Definitely benign No increased uptake—uptake essentially the same
reference lung tissue (generally corresponds to an
Probably benign Uptake substantially less than in blood pool (gene
activity) but greater than in reference lung tissue (
than 0.6–0.8 but less than 1.5–2.0)
Indeterminate Uptake 2–3 times that in reference lung tissue but
pool (generally corresponds to SUV of 1.5–2.0 but
Probably Malignant Uptake greater than in blood pool (blood pool ge
corresponds to an SUV of 2.5)
Definitely Malignant Uptake much greater than in blood pool—anythin
substantially greater than SUV of 2.5appearances of the nodules into account when classify-
ing nodules into the five categories as per standard clin-
ical practice. For example a solid nodule with smooth
well-defined margins and no uptake was likely to be be-
nign whereas a lesion with high uptake and a densely
spiculated margin is likely to be malignant. If based on all
the available information the nodule could not be confi-
dently categorised as either benign or malignant they were
categorised as indeterminate. For indeterminate nodules
on CT, the PET scan was given a stronger weighting than
the CT appearances but for lesions unsuitable for biopsy,
both modalities were considered in arriving at a final diag-
nosis. Accordingly, the initial diagnosis was risk-adapted
and only the incremental diagnostic information of the
gated study was assessed. The 20 scans were reported by
four imaging specialists who each had a minimum of
10 years clinical reporting experience.
Patient follow-up
Patients were followed up until a definitive diagnosis
was obtained. Follow up was obtained for all 20 patients
and compared to the WB-PET and 4D-PET diagnosis. If
the nodule was resected, histopathology was used to
confirm the diagnosis. Any lesions that resolved on sub-
sequent imaging without oncological intervention were
considered of a benign origin.
Statistical analysis
Frequencies were calculated for the five classification types
to compare the frequencies of classification in WB-PET/
CT and 4D-PET/CT scanning. The sensitivity, specificity
and accuracy with confidence intervals were also calcu-
lated to compare the findings of the two scanninglikelihood of Relationship between CT SPN characteristics
and likelihood of malignancy
as in
SUV of 0.6–0.8)
Central laminated or diffuse calcification
Popcorn pattern of calcification
Lesion with cavitations and wall thickness < 1 mm
ral mediastinal
SUV greater
Large (< ;2 cm) dominant nodule with satellite
lesions
Solid nodule with polygonal shape or smooth
and well-defined margin
Diameter < 10 mm; lobulated margin contours
less than in blood
less than 2.5)
All other characteristics not defined in other
likelihood categories
nerally Diameter > 2 cm
Ground-glass opacity with round shape
Mixed ground-glass opacity with central
zone of high attenuation
g Densely spiculated margin, ragged margin Lesion
with cavitations and wall thickness > 16 mm
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of malignant we have calculated the accuracy with indeter-
minate lesions classified as either being all malignant or
all benign. This is the same method employed by Guerra
et. al. to look at the added diagnostic value of 4D-PET/CT
[11]. A McNemars test was used to detect any difference
in the proportion of lesions classified as indeterminate on
WB-PET/CT compared to 4D-PET/CT.
Results
Lesion diagnosis
As outlined in Figure 1, 13 patients had a diagnosis con-
firmed by histopathology, 4 resolved on imaging (mean
6 months, 3.7-11.6 months) and 3 were stable more than
12 months after the PET scan (mean 14 months, 12–18
months). Of note are three patients that were classified a
probably benign on imaging but showed an interval in-
crease in size at an early imaging follow-up. These were
subsequently confirmed as malignant on histopathology
without and interval change in stage. Thus, only 2 patients
underwent biopsy for a non-malignant process and no pa-
tients were inappropriately observed.
Impact of 4D-PET/CT in lesion classification
The proportion of patients in each category and their
subsequent diagnosis are outlined in Figure 1. In this co-
hort, there were no changes in the PET classification of
nodules initially classed as either benign or malignant on
standard WB PET/CT. The only changes in classification
between WB and 4D-PET/CT scans were in lesions ini-
tially classified as indeterminate.
Lesions initially classified as Benign or Malignant on
WB-PET/CT
Fourteen out of the 20 patients were classified as either
benign (8/20 (40%)) or malignant (6/20, (30%)) based onFigure 1 Classification of solitary pulmonary nodules observed on WB
lesions = 20).the WB-PET/CT result. Of these fourteen cases there
was no change in lesion classification with the addition
of the 4D-PET/CT. All six cases classed as malignant,
we subsequently confirmed true positive. Three out of
the eight lesions classified as benign on FDG-PET were
subsequently found to be malignant on follow up indi-
cating they were incorrectly classified on both WB and
4D-PET/CT scans. One of the three incorrectly classi-
fied lesions was a carcinoid, while the other two were
small adenocarcinomas.
Lesions initially classified as indeterminate on WB-PET/CT
Six of the 20 lesions (30%) were initially classified as inde-
terminate on the WB-PET/CT scan. The results for these
six lesions are outlined in Table 2. In four out of these six
lesions, the 4D-PET/CT influenced the reporting phys-
ician to change their classification. However the reduction
in the proportion of indeterminate lesions from 6/20 to
2/20 was not statistically different (p = 0.1336).
In one out of these four cases, the continued absence
of metabolic signal on the 4D-PET/CT in a lower lobe
lesion influenced the physician to classify the lesion as
probably benign, which was found to be correct. In three
out of the four cases higher FDG signal was detected
(SUVmax increase: 1.8-4.8 [167% increase], 1.4-2.0 [43%]
and 1.8-2.5 [34%], respectively) on the 4D-PET/CT scan
leading the reporting physician to classify the lesion as
more likely to be malignant. Two of three of these le-
sions were subsequently found to be benign. Figure 2
shows an example of a 2.6 cm lesion that was initially in-
determinate but changed to probably malignant based
on the additional signal detected on the 4D-PET/CT.
This lesion was subsequently resected and found to be a
granulomatous lesion. Figure 3 shows a case where the
higher SUVmax on the 4D-PET/CT influenced the report-
ing physician to reclassify the lesion from indeterminate-PET/CT and 4D-PET/CT scans and subsequent diagnosis (Total N
Table 2 This table shows the progression of lesions initially categorised as indeterminate on Whole Body PET/CT, any
change in classification with the additional 4D-PET/CT and in lesions final diagnosis
WB-PET/CT finding 4D-PET/CT finding Final diagnosis Method of diagnosis
Indeterminate Indeterminate BENIGN Resolution on imaging
Indeterminate Indeterminate MALIGNANT Lesion Resected - Adenocarcinoma
Indeterminate Probably Benign BENIGN Resolution on imaging
Indeterminate Probably Malignant BENIGN Lesion Resected - Granulomatous
Indeterminate Probably Malignant BENIGN Resolution on imaging
Indeterminate Probably Malignant MALIGNANT Lesion Resected - Carcinoid
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and found to be malignant.
Table 3 shows the relative sensitivity, specificity and
overall accuracy for in initial classification on the WB-
PET/CT alone and then with the addition of the 4D-
PET/CT. If all indeterminate lesions were defined as
malignant irrespective of acquisition method, the 4D-PET/
CT scan had a sensitivity, specificity and accuracy the WB
PET/CT but these results did not reach statistical sig-
nificance. However, when the indeterminate lesions wereFigure 2 Lesion in the Right Lower Lobe was initially indeterminat
The 4D-PET/CT scan (bottom row –SUVmax = 4.8) revealed FDG uptake
lesion as probably malignant. The blue arrow in the top left hand cell
CT scans is then well corrected on the 4D-PET/CT in the bottom rightdefined as benign, the accuracy and specificity of 4D-PET/
CT was lower than WB PET/CT with the addition of
the due to two additional false positive findings that
had been classified as benign on the WB-PET/CT scan
but again the results did not reach statistical signifi-
cance (Table 3).
Discussion
At our facility, the use of PET/CT to classify solitary pul-
monary nodules is restricted to lesions that are eithere based on the WB-PET/CT scan (top row - SUVmax = 1.8).
in the lesion influencing the reporting physician to re-classify the
shows how the significant mis-registration between the PET and
hand panel.
Figure 3 Lesion in the left lower lobe that was original classified on the WB-PET/CT (left column) as indeterminate and was
subsequently changed to probably malignant on the 4D-PET/CT (right column). The SUVmax increased from 1.4 to 2.0. This lesion
was subsequently confirmed as an adenocarcinoma.
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nant, considered to be unsuitable for percutaneous biopsy.
In the latter situation, FDG PET/CT is used both for plan-
ning the best technique and site for biopsy [14] and for
staging in the event that malignancy is confirmed. Accord-
ingly, there is a significant pre-test selection bias in this
prospective series. However, we believe this to be an ap-
propriate clinical setting in which to evaluate the incre-
mental value of respiratory-gated (4D) PET/CT.
We have found that when the reporting physician is able
to classify a lesion as either benign or malignant on con-
ventional WB PET/CT, an additional 4D-PET/CT did notTable 3 Shows the relative sensitivity, specificity and overall
indeterminate lesions were classified as either being Maligna
Indeterminate as malignant
WB-PET/CT 4D-PET C
SENSITIVITY 73% (39-93%) 69% (39-91
SPECIFICITY 56% (21-86%) 71% (29-96
Accuracy 65% (35-87%) 70% (39-90
None of the observed difference were statistically significant.change their diagnosis. The only clinical situation where
the 4D-PET/CT was found to impact the reporting physi-
cian’s classification was when the initial finding on the WB-
PET/CT was considered to be indeterminate. In this study,
the rate of indeterminate findings reduced from 30% to
10% with the addition of 4D-PET/CT. This is consistent
with the work by Guerra and colleagues who noted that
the main discrepancy between WB-PET/CT and 4D-PET/
CT was in indeterminate findings which were reduced from
24.3% to 4.4% with the addition of a 4D-PET/CT [11].
In the four indeterminate lesions that had a change in
classification from indeterminate to probably malignant,accuracy with 95% confidence intervals when
nt (left column) or Benign (right column)
Indeterminate as benign
T WB-PET/CT 4D-PET CT
%) 55% (23-83%) 67% (35-90%)
%) 100% (66-100%) 75% (35-97%)
%) 75% (51-91%) 70% (39-90%)
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the effects of the respiratory motion artefact to provide a
more representative estimation of true FDG-avidity does
not change the inherent weakness of FDG in differentiat-
ing between a malignant lesion and an inflammatory
process (Figures 2 and 3). Additionally, respiratory gat-
ing can’t overcome the issues posed by partial volume
effects or improve the sensitivity of PET in the presence
of low FDG-avidity, as seen in some low-grade malig-
nant nodules including carcinoid tumours.
The results of this prospective cohort is also similar to
that presented by Vicente et al. [12] who showed that in
lesions with low FDG avidity (N = 42) the addition of
4D-PET/CT decreased specificity (100% to 72%) due to
additional false positive findings. However, there was an
increase in the overall accuracy (from 45% to 62%), due
improved sensitivity. As has been shown in a number
of studies, the 4D-PET/CT scanning technique removes
the respiratory motion artefact and reveals the true meta-
bolic signal [7-9]. While an improvement in the sensi-
tivity of detection of malignancy may be desirable, even
at the risk of additional false positives, most tumours
with low FDG-avidity tend to have a less aggressive
natural history and it may be reasonable to observe
these for growth on CT rather than subjecting patients to
the morbidity that can be associated with pathological
characterisation.
It has been proposed that dual time point imaging
may be useful in differentiating benign from malignant
lung nodules [15]. However, a meta analysis did not find
that this technique improved the overall accuracy of
FDG-PET for this indication [15]. This may be because
the lung nodules at both time points are still affected by
respiratory blurring. The dual time point method as-
sumes an increase in SUV uptake is indicative of malig-
nancy but one needs to consider that the measurement
of SUV in moving lesions is less accurate [5,9,11,12]. An
additional confounding factor for lesions subject to the
respiratory motion in standard WB-PET/CT is inaccur-
ate attenuation correction due to mis-registration. The
dual time point method does not address any of these
confounding factors. In this study, the 4D PET/CT was
performed after the WB PET/CT and it is therefore pos-
sible that some of the increased sensitivity observed re-
lated to delayed imaging.
The routine addition of a 4D-PET/CT using this acqui-
sition protocol is unlikely to be feasible for all patients in a
busy clinical PET centre. The described 4D-PET/CT scan-
ning technique requires additional scan time, infrastruc-
ture and patient co-operation. There is also an increase in
radiation dose due to the 4D-CT scan. This is a particu-
larly important consideration in the patient cohort who
may not have any malignancy. Therefore, it is important
to determine when to apply this scanning technique toimprove the overall accuracy of FDG-PET. The results of
this and other studies study suggest that the most efficient
use of 4D-PET/CT is in those pulmonary nodules that are
of an indeterminate nature based on the standard WB-
PET/CT technique. This process requires the reporting
physician to review the WB-PET/CT prior to the patient
leaving the imaging centre. While this can be disruptive
for those patients completing a 4D-PET/CT it will avoid a
lot on unnecessary 4D scanning for lesions that are un-
likely to have their classification impacted by a 4D scan.
A limitation of the data presented is the relatively small
number of patients. However, given that the results are
similar to the larger retrospective cohort of Guerra et al.,
[11] we believe that these prospective findings strengthen
the overall body of evidence demonstrating that 4D-PET/
CT is best applied in indeterminate pulmonary lesions.
In this paper we have also not used a SUVmax cut off
for the classification of malignancy because any cut off
value is arbitrary and certainly an optimal diagnostic
threshold has not been defined for modern time-of-flight
scanners or using respiratory gating to date. The lesion
shown in Figure 3 had a SUVmax of 4.8 but was subse-
quently found to be granulomatous. While this lesion was
incorrectly classified as malignant, in reality the clinical
implication of this result is that malignancy should be ex-
cluded by early pathological characterisation if possible.
Also, as shown in a recent paper by Lee et. al. [16], the de-
gree of FDG uptake is dependant on the tumour type
meaning that an arbitrary cut off value may incorrectly
classify lower grade tumours. It is for these reasons that
an arbitrary SUVmax cut-off value without taking into ac-
count the patient’s likelihood for malignancy is likely to be
less accurate.
With the widespread use of CT to detect solitary pul-
monary nodules there will be an increasing need to use
PET to characterise indeterminate lesions found by this
imaging modality [17]. Adeonocarcinoma is now the
most common lung malignancy, which will challenge the
ability of FDG-PET to correctly classify lesions due to
the variability in glucose uptake across the different type
of adenocarcinomas [16]. An additional 4D-PET cannot
overcome false positive or negatives due to tracer kinetics,
but there may be an impact on management if glucose
uptake sufficiently predicts mitotic behaviour allowing
allocation to a CT observational strategy without con-
cern of interval stage migration. A 4D acquisition may be
a tool to improve the overall accuracy of FDG-PET in this
setting.
Conclusion
The addition of 4D-PET/CT is most likely to have an
impact on those nodules initially classified as indeter-
minate on standard WB-PET/CT. In lesions classified as
benign or malignant on standard WB-PET/CT the addition
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tion. While 4D-PET/CT does improve the measurement
of the metabolic signal, it does not overcome inherent lim-
itations of FDG in differentiating a malignant lesion from
inflammatory processes, correct for partial volume effects
or compensate for the low intrinsic FDG-avidity of some
malignancies.
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